Combined Treatment of Adenoid Cystic Carcinoma With Cetuximab and IMRT Plus C12 Heavy Ion Boost - ACCEPT - (ACC, Erbitux, and Particle Therapy); Phase I/II Feasibility Study.

Trial Profile

Combined Treatment of Adenoid Cystic Carcinoma With Cetuximab and IMRT Plus C12 Heavy Ion Boost - ACCEPT - (ACC, Erbitux, and Particle Therapy); Phase I/II Feasibility Study.

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 27 May 2014

At a glance

  • Drugs Cetuximab (Primary)
  • Indications Head and neck cancer
  • Focus Adverse reactions
  • Acronyms ACCEPT
  • Most Recent Events

    • 23 Apr 2013 Planned end date changed from 1 Oct 2015 to 1 Jul 2017 as reported by ClinicalTrials.gov.
    • 13 Sep 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top